Using efficacy, safety, and cost data to support a formulary decision regarding thrombolytic therapy

Mandy C. Leonard, Kenneth M. Shermock

Research output: Contribution to journalReview article

Abstract

When urokinase was withdrawn from the market, alternative thrombolytics such as alteplase and reteplase needed to be evaluated for peripheral vascular disease (PVD). The efficacy, safety, and cost of these agents were evaluated formally by the Department of Pharmacy and presented to the Pharmacy and Therapeutics Committee. No published data support a difference in efficacy or safety between these agents. A cost analysis estimated the average total cost of care was higher for patients treated with reteplase ($4,556) compared with alteplase ($2,139). Therefore, alteplase was determined to be a more cost-effective thrombolytic agent to treat PVD.

Original languageEnglish (US)
Pages (from-to)150-155
Number of pages6
JournalSeminars in vascular surgery
Volume14
Issue number2
DOIs
StatePublished - Jan 1 2001

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Using efficacy, safety, and cost data to support a formulary decision regarding thrombolytic therapy'. Together they form a unique fingerprint.

  • Cite this